Sobi Reports Strong Second Quarter Growth
Swedish biopharmaceutical company Sobi announced its Q2 2026 results, showing significant revenue increases driven by key product sales.
Swedish Orphan Biovitrum AB (Sobi) has reported a substantial increase in revenue for the second quarter of 2026. Total revenue rose by 27 percent to SEK 7,842 million compared to the same period in the previous year, operating at constant exchange rates showed a 29 percent increase.
The hematology division saw a 27 percent revenue increase to SEK 5,726 million, primarily due to strong sales of Altuvoct and Doptelet. The immunology division also experienced significant growth with a 37 percent increase in revenue, reaching SEK 1,711 million, driven by Gamifant and Kineret sales. Despite the financial success, Sobi received a Complete Response Letter from regulatory authorities regarding manufacturing for its NASP product, although the company plans to resubmit. In a positive development for its pipeline, Sobi announced positive topline results from the pivotal Phase 3 REDUCE 2 study for Pozdeutinurad in treating gout.
Sobi has updated its outlook for 2026, now anticipating revenue to grow by a mid-to-high teens percentage at constant exchange rates. The adjusted EBITA margin is projected to be in the mid-to-high 30s percentage range of revenue. In 2025, Sobi, which focuses on rare diseases, reported revenues of SEK 28 billion.